Drug intelligence / Profile preview

lipotecan

Development stage: Phase 2
Lead developer: Taiwan Liposome Company
Modality: Nanoparticles → Drug Delivery Systems, Small Molecules
Administration: Intravenous

Overview

Lipotecan is a novel camptothecin analog and topoisomerase I inhibitor developed as an anticancer agent. It is formulated as a liposomal preparation (TLC388) to enhance delivery and efficacy. Lipotecan induces immunogenic cell death, increases cancer immunogenicity, and remodels the tumor microenvironment to provoke antitumor immune responses. Preclinical studies suggest it can enhance the therapeutic response to radiotherapy and immune checkpoint inhibitors by activating STING pathways. Clinical trials have evaluated its use in advanced solid tumors, hepatocellular carcinoma, and poorly differentiated neuroendocrine carcinomas[8][10].

Brand names: Lipotecan
Other names: TLC388TLC-388TLC 388Lipotecan hydrochloride

Targets

TOP1 (DNA Topoisomerase I)

Beyond the preview

Go deeper on lipotecan.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on lipotecan.

Explore the full profile